ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cetirizine

Also written as “Cetirizine (Zyrtec)”, “AC-170 0.24%” and “Ceterizine”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Hypersensitivity · Urticaria · Conjunctivitis, Allergic · Rhinitis, Allergic, led by 12 companies.

Drug pageCetirizine: every studyMany companies study it; this page follows only the 31 they lead. All 67 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 7, 201131 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aciex Therapeuticsits history only70 open or runningphase 3since Apr 7, 2011Apr 7, 2011none ahead
GlaxoSmithKline50 open or runningphase 4since Aug 1, 2013Jun 19, 2007none ahead
JDP Therapeuticsits history only30 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Johnson & Johnsonits history only30 open or runningphase 4since Sep 30, 2016Mar 23, 2011none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Feb 4, 2010Feb 4, 2010none ahead
Novartisits history only20 open or runningphase 1since Apr 13, 2009Apr 13, 2009none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Oct 17, 2008Oct 17, 2008none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lunan Pharmaceutical Groupits history only11 open or runningphase 3since Feb 6, 2025Feb 6, 2025none ahead

Also a collaborator on its studies: Algorithme Pharma, ORA, Pfizer and Ohm Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 19, 2007First study: phase 3 study in Rhinitis, Allergic, PerennialFirst studyNCT00490204 · 239 enrolled · Japan
  2. Feb 24, 2009Phase 2 study in Rhinitis, Allergic, SeasonalNCT00851344 · 54 enrolled · Germany
  3. Aug 27, 2009Phase 2 study in Rhinitis, Allergic, SeasonalNCT00972504 · 54 enrolled · Germany
  4. Jun 23, 2011Phase 1 study in DermatitisNCT02447393 · 20 enrolled · Japan
  5. Aug 1, 2013Phase 4 study in RhinitisNCT01916226 · 682 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01916226Rhinitis · United States4CompletedOct 1, 2013682
NCT02447393Dermatitis · Japan1CompletedApr 30, 200820
NCT00972504Rhinitis, Allergic, Seasonal · Germany2CompletedAug 1, 200954
NCT00851344Rhinitis, Allergic, Seasonal · Germany2CompletedNov 200854
NCT00490204Rhinitis, Allergic, Perennial · Japan3CompletedOct 3, 2007239

How it is read

Names in the registry

  • “Cetirizine”, 6 entries
  • “Cetirizine (Zyrtec)”, 5 entries
  • “AC-170 0.24%”, 5 entries
  • “Ceterizine”, 2 entries
  • “cetirizine”, 2 entries

Codes read as this program: JDP205.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.